Boston Scientific Announces Results for First Quarter 2024

Boston Scientific Q1 hit by woes over mesh, paclitaxel, sterilization

Boston Scientific said Wednesday morning its first quarter earnings grew 4.8% to roughly $2.5 billion, falling short of prior company ...

Boston Scientific (BSX) Beats Expectations with $3.8 Billion in Q1 ...

Boston Scientific Corporation (NYSE: BSX) reported a significant growth in net sales for the first quarter of 2024, reaching $3.856 billion.

BSX / Boston Scientific Corporation - SEC Filings, Annual Report ...

2024-04-24, Boston Scientific Announces Results for First Quarter 2024). 2024-02-27, Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes). 2024- ...

Boston Scientific Announces Conference Call Discussing Third ...

The company will also host a virtual investor event on Wednesday, October 30, 2024, from 4:00 – 5:00 p.m. ET following Transcatheter ...

Boston Scientific Corporation (BSX) Q1 2024 Earnings Call Transcript

We issued a press release earlier this morning announcing our Q1 results, which included reconciliations of the non-GAAP measures used in the ...

BSX Boston Scientific Corporation - Quantisnow

23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.209 billion during the third quarter of 2024, growing 19.4 percent ...

Boston Scientific (BSX)major events announcements - 富途牛牛

Ratings · Boston Scientific | 8-K: Boston Scientific Announces Results for Third Quarter 2024 · Boston Scientific | 8-K: Current report · Boston Scientific | 8-K: ...

Boston Scientific Beats Forecasts, Boosts Outlook on Booming Heart ...

Boston Scientific exceeded first-quarter profit and sales forecasts on demand for its cardiovascular devices. · The results were lifted by ...

Boston Scientific Announces 2023 Investor Day Meeting and ...

"Our results in the first half of 2023 exceeded our expectations and demonstrated the strength of our category leadership strategy, commitment ...

Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.55, $0.04 better than the analyst estimate of $0.51. Revenue for the quarter came in at ...

Boston Scientific's stock heads for record high as earnings shine ...

Sales of cardiovascular products rose 15.9% in the quarter, helping Boston Scientific beat estimates.

Boston Scientific Corporation Announces Results For Fourth Quarter ...

Delivered fourth quarter revenue growth of 10 percent in Cardiovascular, 5 percent in Rhythm Management, and 4 percent in MedSurg, all on a ...

Boston Scientific raises annual profit forecast on heart devices ...

Boston Scientific raised its full-year profit forecast on Wednesday on the back of strong demand for its heart devices, ...

Boston Scientific Co. (NYSE:BSX) Shares Bought by Natixis ...

Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion for the quarter, ...

$BSX Boston Scientific Q1 2024 Earnings Conference Call - YouTube

04/24/2024 Q&A: 21:47 Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional ...

Shockwave Medical announces huge Q1 growth, including ...

The company reported a Q1 revenue of $161.1 million, up 72% from Q1 in 2022. Both gross profit and net income were also up considerably when ...

Boston Scientific on LinkedIn: Interested in our Q2 2024 financial ...

We are excited to announce our financial results for the fourth quarter and full fiscal year 2024! Congratulations to our entire team for ...

Why Is Boston Scientific Stock Trading Higher On Wednesday?

Boston Scientific reports impressive Q1 earnings, with revenues of $3.86 billion, beating estimates. Cardiovascular segment leads with $2.4 ...

Boston Scientific Announces Results for First Quarter Ended March ...

"We are very pleased that we achieved record company sales for the quarter, including 15 percent year-over-year constant currency growth in our Endosurgery ...

Boston Scientific gets Q4 boost from heart, urology sales

Boston Scientific said net income rebounded in the fourth quarter, supported by higher sales of both cardiovascular and medical/surgical products.